Alzheimer's disease: The right drug, the right time

See allHide authors and affiliations

Science  14 Dec 2018:
Vol. 362, Issue 6420, pp. 1250-1251
DOI: 10.1126/science.aau0437

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Alzheimer's disease (AD) is an age-associated neurodegenerative disease that is reaching epidemic proportions as a result of the aging of the world's population. Impressive gains in our understanding of AD pathogenesis have not yet translated into disease-modifying therapies that benefit patients. Is this because the knowledge that guides target identification and, hence, therapeutics, is insufficient? Are current clinical trial designs not optimal? Or are other factors contributing? Here, we highlight the challenges of developing effective AD therapies and discuss how lessons learned from failed trials must be implemented to increase the likelihood of success.